Weizman, Abraham

Lowered DHEA-S plasma levels in adult individuals with autistic disorder

Strous, R. D., Golubchik, P., Maayan, R., Mozes, T., Tuati-Werner, D., Weizman, A., & Spivak, B. (2005) · European Neuropsychopharmacology

Autism Spectrum Disorder ResearchSexual Differentiation and Disorders

Cited by 59

Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy

Marom, S., Gilboa-Schechtman, E., Aderka, I. M., Weizman, A., & Hermesh, H. (2009) · Depression and Anxiety

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychological Treatments and Assessments

Cited by 55

Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS

Michaelovsky, E., Gothelf, D., Korostishevsky, M., Frisch, A., Burg, M., Carmel, M., Steinberg, T., Inbar, D., Apter, A., & Weizman, A. (2008) · The International Journal of Neuropsychopharmacology

Schizophrenia research and treatmentGenomic variations and chromosomal abnormalities

Cited by 53

Neutrophil to-lymphocyte and platelet-to-lymphocyte ratios as biomarkers for suicidal behavior in children and adolescents with depression or anxiety treated with selective serotonin reuptake inhibitors

Amitai, M., Kaffman, S., Kroizer, E., Lebow, M., Magen, I., Benaroya-Milshtein, N., Fennig, S., Weizman, A., Apter, A., & Chen, A. (2022) · Brain, Behavior, and Immunity

Suicide and Self-Harm StudiesTryptophan and brain disorders

Cited by 51

When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations

Manor, I., Rozen, S., Zemishlani, Z., Weizman, A., & Zalsman, G. (2011) · Clinical Neuropharmacology

Attention Deficit Hyperactivity DisorderDementia and Cognitive Impairment Research

Cited by 45

Neuroprotective effect of Ro5-4864 following brain injury

Soustiel, J. F., Zaaroor, M., Vlodavsky, E., Veenman, L., Weizman, A., & Gavish, M. (2008) · Experimental Neurology

Mitochondrial Function and PathologyNeuroprotection in Cerebral Ischemia

Cited by 44

EEG p-adic quantum potential accurately identifies depression, schizophrenia and cognitive decline

Shor, O., Glik, A., Yaniv-Rosenfeld, A., Valevski, A., Weizman, A., Khrennikov, A., & Benninger, F. (2021) · PLOS ONE

EEG and Brain-Computer Interfacesp-Adic Analysis and Mathematical Physics

Cited by 38

Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial

Golubchik, P., Sever, J., Zalsman, G., & Weizman, A. (2008) · International Clinical Psychopharmacology

Attention Deficit Hyperactivity DisorderPersonality Disorders and Psychopathology

Cited by 36

Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study.

Avital, A., Gross-Isseroff, R., Stryjer, R., Hermesh, H., Weizman, A., & Shiloh, R. (2009) · European Neuropsychopharmacology

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 33

Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment

Krivoy, A., Hochman, E., Sendt, K.-V., Hollander, S., Vilner, Y., Selakovic, M., Weizman, A., & Taler, M. (2018) · Schizophrenia Research

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 33

Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients

Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Weizman, A., & Ritsner, M. S. (2011) · Clinical Neuropharmacology

Schizophrenia research and treatmentTryptophan and brain disorders

Cited by 31

EEG-based spatio-temporal relation signatures for the diagnosis of depression and schizophrenia

Shor, O., Yaniv-Rosenfeld, A., Valevski, A., Weizman, A., Khrennikov, A., & Benninger, F. (2023) · Scientific Reports

EEG and Brain-Computer InterfacesEmotion and Mood Recognition

Cited by 30

A history of prolonged childhood sexual abuse is associated with more severe clinical presentation of borderline personality disorder in adolescent female inpatients – A naturalistic study

Turniansky, H., Ben-Dor, D., Krivoy, A., Weizman, A., & Shoval, G. (2019) · Child Abuse & Neglect

Personality Disorders and PsychopathologyChild Abuse and Trauma

Cited by 29

Neuropsychological mechanisms of Digit Symbol Substitution Test impairment in Asperger Disorder

Yoran-Hegesh, R., Kertzman, S., Vishne, T., Weizman, A., & Kotler, M. (2009) · Psychiatry Research

Autism Spectrum Disorder ResearchDevelopmental and Educational Neuropsychology

Cited by 25

Exposure to the Lebanon War of 2006 and effects on alcohol use disorders: the moderating role of childhood maltreatment

Keyes, K. M., Shmulewitz, D., Greenstein, E., McLaughlin, K., Wall, M., Aharonovich, E., Weizman, A., Frisch, A., Spivak, B., Grant, B. F., et al. (2014) · Drug and Alcohol Dependence

Child Abuse and TraumaPosttraumatic Stress Disorder Research

Cited by 21

Risk of readmission in compulsorily and voluntarily admitted patients

Valevski, A., Olfson, M., Weizman, A., & Shiloh, R. (2007) · Social Psychiatry and Psychiatric Epidemiology

Healthcare Decision-Making and RestraintsPsychiatric care and mental health services

Cited by 21

Efficacy of Reboxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Boys With Intolerance to Methylphenidate: An Open-Label, 8-Week, Methylphenidate-Controlled Trial

Cohen-Yavin, I., Yoran-Hegesh, R., Strous, R. D., Kotler, M., Weizman, A., & Spivak, B. (2009) · Clinical Neuropharmacology

Attention Deficit Hyperactivity DisorderBehavioral and Psychological Studies

Cited by 16

Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients

Iancu, I., Tchernihovsky, E., Maayan, R., Poreh, A., Dannon, P., Kotler, M., Weizman, A., & Strous, R. D. (2007) · European Neuropsychopharmacology

Schizophrenia research and treatmentSmoking Behavior and Cessation

Cited by 14

The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study

Weinberger, R., Weisman, O., Guri, Y., Harel, T., Weizman, A., & Gothelf, D. (2018) · European Psychiatry

Schizophrenia research and treatmentGenomic variations and chromosomal abnormalities

Cited by 14